Amoxicillin-clavulanic acid for treating drug-resistant Mycobacterium tuberculosis.
case_report · Level V
Where this comes from
- Record sourced from PubMed, PMID 1901260.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
This report describes two patients with multidrug resistant tuberculosis who were successfully treated with the addition of amoxicillin-clavulanic acid to second-line drugs. Mycobacterium tuberculosis possesses a beta-lactamase contributing to its resistance to beta-lactam antibiotics. The combination of clavulanic acid, a beta-lactamase inhibitor, and amoxicillin has been shown bactericidal for M tuberculosis in vitro. These data suggest that resistant tuberculosis may warrant a trial of treatment including amoxicillin-clavulanic acid.
Medical subject headings
- Amoxicillin
- Clavulanic Acids
- Mycobacterium tuberculosis
- Tuberculosis, Pulmonary
- beta-Lactamase Inhibitors